Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow SILENCE THERAPEUTICS PLC

Get SEC filing alerts via email and in your feed for SILENCE THERAPEUTICS PLC

SLN SLNCF

SILENCE THERAPEUTICS PLC

About SILENCE THERAPEUTICS PLC

Silence Therapeutics plc is a biotechnology company specializing in RNA interference (RNAi) therapeutics, focusing on developing siRNA molecules to target diseases with significant unmet medical needs. Its key products include divesiran for polycythemia vera and zerlasiran for cardiovascular disease linked to elevated lipoprotein(a). With a robust pipeline and proprietary mRNAi GOLD platform, Silence aims to address critical health challenges while exploring partnerships for further development and commercialization.
This description was generated via AI from an annual report. Updated 8 months ago.
silence-therapeutics.com

Latest SEC Filings from SILENCE THERAPEUTICS PLC

1
1
SILENCE THERAPEUTICS PLC Silence Therapeutics Reports Q1 2026 Revenue Growth to $422,000 Amid Continued Net Loss

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
SILENCE THERAPEUTICS PLC Silence Therapeutics Reports Significant Revenue Decline and Increased Operating Losses for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
SILENCE THERAPEUTICS PLC Silence Therapeutics Reports Significant Revenue Decline and Increased Net Losses for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
SILENCE THERAPEUTICS PLC Silence Therapeutics Reports Significant Revenue Decline and Increased R&D Expenses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
SILENCE THERAPEUTICS PLC Silence Therapeutics Reports Significant Revenue Decline and Increased Losses in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments